Published in J Autoimmun on July 13, 2013
The diagnosis of primary biliary cirrhosis. Autoimmun Rev (2014) 1.03
AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis. J Autoimmun (2015) 0.81
Primary biliary cirrhosis: From bench to bedside. World J Gastrointest Pharmacol Ther (2015) 0.78
Concurrent autoimmune pancreatitis and primary biliary cirrhosis: a rare case report and literature review. BMC Gastroenterol (2014) 0.75
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol (2007) 5.77
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology (2007) 2.36
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med (2011) 2.03
A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology (2008) 2.02
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
Primary biliary cirrhosis. Lancet (2003) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology (2011) 1.80
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol (2008) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol (2004) 1.66
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology (2013) 1.64
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc (2011) 1.62
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Primary sclerosing cholangitis. Lancet (2013) 1.59
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Noninvasive assessment of liver fibrosis. Hepatology (2011) 1.57
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53
"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2005) 1.48
Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2003) 1.47
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Research productivity of graduates from 3 physician-scientist training programs. Am J Med (2008) 1.44
The value of observational research in liver diseases. Hepatology (2011) 1.43
Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol (2008) 1.41
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology (2013) 1.35
Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.33
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Abdominal magnetic resonance elastography. Top Magn Reson Imaging (2009) 1.26
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res (2011) 1.23
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology (2002) 1.20
Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol (2010) 1.17
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Bone disease in patients with primary sclerosing cholangitis. Gastroenterology (2010) 1.15
The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int (2012) 1.15
Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging (2011) 1.14
Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol (2002) 1.14
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.12
Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology (2008) 1.11
Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol (2003) 1.10
Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol (2005) 1.10
Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis (2008) 1.09
Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver disease. AJR Am J Roentgenol (2011) 1.09
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol (2006) 1.07
Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology (2003) 1.07
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology (2004) 1.06
Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol (2007) 1.05
The cytoplasmic dot staining pattern is detected in a subgroup of patients with primary biliary cirrhosis. J Rheumatol (2005) 1.05
Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci (2010) 1.05
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology (2005) 1.05
Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol (2011) 1.02
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis (2006) 1.02
Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosis. Gastroenterology (2006) 1.00
When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol (2003) 1.00
Evaluating sex and gender competencies in the medical curriculum: a case study. Gend Med (2012) 1.00
Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2012) 0.99
Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol (2010) 0.99
Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol (2002) 0.99
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol (2007) 0.99
Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol (2009) 0.99
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol (2007) 0.98
Non-invasive detection of liver fibrosis: MR imaging features vs. MR elastography. Abdom Imaging (2015) 0.98
Living donor liver transplantation using a right lobe graft in an adult with situs inversus. Liver Transpl (2005) 0.97
Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int (2013) 0.97
Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol (2013) 0.97